Skip to main content
Premium Trial:

Request an Annual Quote

Agilent Board Approves $1.14B Share Buyback Program

NEW YORK (GenomeWeb) – Agilent Technologies today announced that its board has approved a share repurchase program for up to a $1.14 billion. 

The buyback program will run through Nov. 1, 2018 and will begin either on Nov. 1, 2015 or when Agilent's previous buyback program is completed. The existing program has $365 million remaining, the Santa Clara, California-based firm said. 

Earlier this month, Agilent reported a 3 percent drop in its fiscal second quarter revenues.

The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.